Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
NCT ID: NCT03970096
Last Updated: 2025-09-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
120 participants
INTERVENTIONAL
2019-11-19
2028-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
NCT06001385
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
NCT02220985
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
NCT06859424
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
NCT01028716
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
NCT03128359
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
ARM A: Patients are assigned to 1 of 2 arms.
ARM A1 (TBI BASED): Patients undergo total-body irradiation (TBI) twice daily (BID) on days -10 to -7, and receive thiotepa intravenously (IV) over 3 hours on days -6 and -5, fludarabine IV over 30 to 60 minutes on days -6 to -2, tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day -1, CD34+ enriched CD45RA-depleted donor T-lymphocytes IV on day 0, and methotrexate IV on days 1, 3, 6, and 11. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid).
ARM A2 (BUSULFAN BASED): Patients receive fludarabine IV over 30 to 60 minutes on days -6 to -2, busulfan IV over 180 minutes on days -5 to -2, and undergo TBI BID on day -1. Patients also receive tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day -1, CD34+ enriched CD45RA-depleted donor T-lymphocytes IV on day 0, and methotrexate IV on days 1, 3, 6, and 11. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid).
ARM C: Patients are assigned to 1 of 2 arms.
ARM C1: Patients undergo TBI BID on days -4 to -2 or -3 to -1, and receive PBSC IV on day 0. Patients also receive cyclophosphamide IV over 1 to 2 hours on days 3 and 4, and tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day 5 approximately 24 hours after the end of the second dose of cyclophosphamide. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid).
ARM C2: Patients receive fludarabine IV over 30 to 60 minutes on days -5 to -2, busulfan IV over 180 minutes on days -5 to -2, PBSC IV on day 0, cyclophosphamide IV over 1 to 2 hours on days 3 and 4, and tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day 5 approximately 24 hours after the end of the second dose of cyclophosphamide. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid).
ARM D: (DISCONTINUED NOVEMBER 2021): Patients are assigned to 1 of 2 arms.
ARM D1: Patients undergo TBI BID on days -6 to -4, and receive cyclophosphamide IV over 1 hour on days -3 to -2, tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day -1, PBSC IV on day 0, and methotrexate IV on days 1, 3, 6, and 11. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid).
ARM D2: Patients receive busulfan IV over 180 minutes on days -8 to -5, cyclophosphamide IV over 1 hour on days -3 to -2, tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day -1, PBSC IV on day 0, and methotrexate IV on days 1, 3, 6, and 11. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid).
All patients also undergo bone marrow aspiration/biopsy, echocardiogram (ECHO) or multigated acquisition (MUGA) scan, and collection of blood samples throughout the trial.
After completion of study treatment, patients are followed up at days 7, 14, 21, 28, 56, 80, 180, and 270 and at 1, 1.5, and 2 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A1 (TBI, TnD)
Patients undergo TBI BID on days -10 to -7, and receive thiotepa IV over 3 hours on days -6 and -5, fludarabine IV over 30 to 60 minutes on days -6 to -2, tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day -1, CD34+ enriched CD45RA-depleted donor T-lymphocytes IV on day 0, and methotrexate IV on days 1, 3, 6, and 11. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid). Patients also undergo bone marrow aspiration/biopsy, ECHO or MUGA scan, and collection of blood samples throughout the trial.
Total-Body Irradiation
Undergo TBI
Thiotepa
Given IV
Fludarabine
Given IV
Tacrolimus
Given IV
Allogeneic CD34+-enriched and CD45RA-depleted PBSCs
Given IV
Methotrexate
Given IV
Cyclosporine
Given IV
Sirolimus
Given IV
Bone Marrow Aspiration and Biopsy
Undergo bone marrow aspiration/biopsy
Echocardiography
Undergo ECHO
Multigated Acquisition Scan
Undergo MUGA
Biospecimen Collection
Undergo blood sample collection
Arm A2 (busulfan, TnD)
Patients receive fludarabine IV over 30 to 60 minutes on days -6 to -2, busulfan IV over 180 minutes on days -5 to -2, and undergo TBI BID on day -1. Patients also receive tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day -1, CD34+ enriched CD45RA-depleted donor T-lymphocytes IV on day 0, and methotrexate IV on days 1, 3, 6, and 11. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid). Patients also undergo bone marrow aspiration/biopsy, ECHO or MUGA scan, and collection of blood samples throughout the trial.
Fludarabine
Given IV
Tacrolimus
Given IV
Allogeneic CD34+-enriched and CD45RA-depleted PBSCs
Given IV
Methotrexate
Given IV
Cyclosporine
Given IV
Sirolimus
Given IV
Busulfan
Given IV
Bone Marrow Aspiration and Biopsy
Undergo bone marrow aspiration/biopsy
Echocardiography
Undergo ECHO
Multigated Acquisition Scan
Undergo MUGA
Biospecimen Collection
Undergo blood sample collection
Arm C1 (TBI, PTCy, tacrolimus)
Patients undergo TBI BID on days -4 to -2 or -3 to -1, and receive PBSC IV on day 0. Patients also receive cyclophosphamide IV over 1 to 2 hours on days 3 and 4, and tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day 5. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid). Patients also undergo bone marrow aspiration/biopsy, ECHO or MUGA scan, and collection of blood samples throughout the trial.
Total-Body Irradiation
Undergo TBI
Tacrolimus
Given IV
Cyclophosphamide
Given IV
Peripheral Blood Stem Cell
Given IV
Cyclosporine
Given IV
Sirolimus
Given IV
Bone Marrow Aspiration and Biopsy
Undergo bone marrow aspiration/biopsy
Echocardiography
Undergo ECHO
Multigated Acquisition Scan
Undergo MUGA
Biospecimen Collection
Undergo blood sample collection
Arm C2 (busulfan, PTCy, tacrolimus)
Patients receive fludarabine IV over 30 to 60 minutes on days -5 to -2, busulfan IV over 180 minutes on days -5 to -2, PBSC IV on day 0, cyclophosphamide IV over 1 to 2 hours on days 3 and 4, and tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day 5. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid). Patients also undergo bone marrow aspiration/biopsy, ECHO or MUGA scan, and collection of blood samples throughout the trial.
Fludarabine
Given IV
Tacrolimus
Given IV
Cyclophosphamide
Given IV
Peripheral Blood Stem Cell
Given IV
Cyclosporine
Given IV
Sirolimus
Given IV
Busulfan
Given IV
Bone Marrow Aspiration and Biopsy
Undergo bone marrow aspiration/biopsy
Echocardiography
Undergo ECHO
Multigated Acquisition Scan
Undergo MUGA
Biospecimen Collection
Undergo blood sample collection
Arm D1 (TBI, tacrolimus, methotrexate) [DISCONTINUED NOVEMBER 2021]
Patients undergo TBI BID on days -6 to -4, and receive cyclophosphamide IV over 1 hour on days -3 to -2, tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day -1, PBSC IV on day 0, and methotrexate IV on days 1, 3, 6, and 11. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid). Patients also undergo bone marrow aspiration/biopsy, ECHO or MUGA scan, and collection of blood samples throughout the trial.
Total-Body Irradiation
Undergo TBI
Tacrolimus
Given IV
Methotrexate
Given IV
Cyclophosphamide
Given IV
Peripheral Blood Stem Cell
Given IV
Cyclosporine
Given IV
Sirolimus
Given IV
Bone Marrow Aspiration and Biopsy
Undergo bone marrow aspiration/biopsy
Echocardiography
Undergo ECHO
Multigated Acquisition Scan
Undergo MUGA
Biospecimen Collection
Undergo blood sample collection
Arm D2 (busulfan, tacrolimus, methotrexate) [DISCONTINUED NOVEMBER 2021]
Patients receive busulfan IV over 180 minutes on days -8 to -5, cyclophosphamide IV over 1 hour on days -3 to -2, tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day -1, PBSC IV on day 0, and methotrexate IV on days 1, 3, 6, and 11. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid). Patients also undergo bone marrow aspiration/biopsy, ECHO or MUGA scan, and collection of blood samples throughout the trial.
Tacrolimus
Given IV
Methotrexate
Given IV
Cyclophosphamide
Given IV
Peripheral Blood Stem Cell
Given IV
Cyclosporine
Given IV
Sirolimus
Given IV
Busulfan
Given IV
Bone Marrow Aspiration and Biopsy
Undergo bone marrow aspiration/biopsy
Echocardiography
Undergo ECHO
Multigated Acquisition Scan
Undergo MUGA
Biospecimen Collection
Undergo blood sample collection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Total-Body Irradiation
Undergo TBI
Thiotepa
Given IV
Fludarabine
Given IV
Tacrolimus
Given IV
Allogeneic CD34+-enriched and CD45RA-depleted PBSCs
Given IV
Methotrexate
Given IV
Cyclophosphamide
Given IV
Peripheral Blood Stem Cell
Given IV
Cyclosporine
Given IV
Sirolimus
Given IV
Busulfan
Given IV
Bone Marrow Aspiration and Biopsy
Undergo bone marrow aspiration/biopsy
Echocardiography
Undergo ECHO
Multigated Acquisition Scan
Undergo MUGA
Biospecimen Collection
Undergo blood sample collection
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Acute lymphocytic leukemia (ALL) in first or subsequent morphological remission (\< 5% marrow blasts by morphology).
* Acute myeloid leukemia (AML) in first or subsequent morphological remission (\< 5% marrow blasts by morphology).
* Other acute leukemia or related neoplasm (including but not limited to 'mixed phenotype' 'biphenotypic', 'acute undifferentiated' or 'ambiguous lineage' acute leukemia, blastic plasmacytoid dendritic cell neoplasm, lymphoblastic lymphoma, Burkitt leukemia/lymphoma, mast cell leukemia, chronic myeloid leukemia \[CML\] with blast crisis or other chronic myeloproliferative neoplasm) in first or subsequent morphological remission (\<5% marrow blasts by morphology).
* Myelodysplastic syndrome (MDS) with a history of excess blasts (≥ approximately 5% in marrow blasts by morphology) and a history of receiving cytoreductive therapy (including but not limited to BCL-2 inhibitors or cytotoxic chemotherapy) within the past 3 months.
* Patient age 1-60 years old (inclusive) at the time of informed consent
* Patients aged 1-50 years old (inclusive) are eligible for TBI-based conditioning regimens.
* Patients aged 1-60 years old (inclusive) are eligible for busulfan-based conditioning regimens (with or without TBI 4 Gy).
* Patient with an HLA-matched (HLA-A, B, C, DRB1, and DQB1 matched) related or unrelated donor capable of donating PBSC.
* Recipient informed consent/assent and/or legal guardian permission must be obtained.
* DONOR: HLA-matched related and unrelated donors (HLA-A, B, C, DRB1 and DQB1 matched based on high-resolution typing).
* DONOR: \>= 18 years old.
* DONOR: Willing to donate PBSC.
* DONOR: Matched related donors:
* Must give informed consent using the related donor informed consent form.
* Must meet institutional donor eligibility criteria or be ineligible with statement that the donor is a first or second degree relative (exception 21 Code of Federal Regulations \[CFR\] 1271.65(b)(i)).
* DONOR: Matched unrelated donors:
* Must consent according to the applicable National Marrow Donor Program (NMDP) donor regulatory requirements.
* Must meet eligibility criteria as defined by the NMDP or be ineligible with statement of urgent medical need (exception 21 CFR 1271.65(b)(iii)).
Exclusion Criteria
* Patients on other experimental protocols for prevention of GVHD.
* Patient weight:
* Patients with HLA-matched related donors will be excluded if they weigh \>= 110 kg.
* Patients with HLA-matched unrelated donors will be excluded if they weigh \>= 110 kg and must be discussed with the Fred Hutch protocol principal investigator (PI) if they weigh \>= 90 kg.
* Patients who are positive for human immunodeficiency virus (HIV)-1, HIV-2, human T-cell lymphotropic virus (HTLV)1 or HTLV2.
* Patients with uncontrolled infections for whom myeloablative HCT is considered contraindicated by the consulting infectious disease physician; i.e. patients with active infections require infectious disease consultation and documentation by the infectious disease team that myeloablative HCT is not considered to be contraindicated. Upper respiratory tract infection is not considered to represent an uncontrolled infection in this context.
* Patients with organ dysfunction, including:
* Renal insufficiency (creatinine \> 1.5 mg/dl) at the time of evaluation for the protocol. Patients with a known history of creatinine \> 1.5 mg/dl or a current serum creatinine above the normal range for age must have a current creatinine clearance of \> 60 ml/min/1.73 m\^2 (measured by 24-hr urine specimen or nuclear glomerular filtration rate \[GFR\]).
* Left ventricular ejection fraction \< 45%.
* Carbon monoxide diffusing capability (DLCO) corrected \< 60%. Patients who are unable to perform pulmonary function tests (for example, due to young age and/or developmental status) will be excluded if the oxygen (O2) saturation is \< 92% on room air.
* Liver function abnormality. Patients who have liver function test (LFT)s (specifically, total bilirubin, aspartate aminotransferase \[AST\] or alanine aminotransferase \[ALT\]) \>= twice the upper limit of normal should be evaluated by a gastrointestinal (GI) physician unless there is a clear precipitating factor (such as an azole, MTX, trimethoprim-sulfamethoxazole, or another drug). If the GI physician considers that HCT on the protocol is contraindicated, that patient will be excluded from the protocol. Patients with Gilbert's syndrome require GI physician consultation but may be included on the protocol. Patients with no other known liver function abnormality or with reversible drug-related transaminitis do not necessarily require GI consultation and may be included on the protocol.
* Patients who have received previous myeloablative allogeneic or autologous transplantation.
* Patients with a life expectancy \< 12 months from co-existing disease other than the leukemia or MDS.
* Patients who are pregnant or breast-feeding.
* Patients of childbearing age who are presumed to be fertile and are unwilling to use an effective birth control method or refrain from sexual intercourse during and for 12 months post-HCT.
* Patients with any other significant medical conditions that would make them unsuitable for transplantation, as determined by the PI.
* Patients with a known hypersensitivity to tacrolimus or MTX
* Patients who have received checkpoint inhibitors within three months of transplantation unless an exception is made by the PI
* DONOR: Donors who are HIV-1, HIV-2, HTLV-1, HTLV-2 seropositive or with active hepatitis B or hepatitis C virus infection. Test must be performed using Food and Drug Administration (FDA) licensed, cleared, and approved test kits (serological and/or nucleic acid amplification test \[NAT\] and/or other approved testing) in a Clinical Laboratory Improvement Act (CLIA)-certified laboratory.
* Unrelated donors donating outside of the USA.
1 Year
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Fred Hutchinson Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marie Bleakley
Role: PRINCIPAL_INVESTIGATOR
Fred Hutch/University of Washington Cancer Consortium
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Moffitt Cancer Center
Tampa, Florida, United States
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, United States
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
9749
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2019-03188
Identifier Type: REGISTRY
Identifier Source: secondary_id
RG1005364
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.